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Abstract: Asian Indian dyslipidemia is characterized by: borderline high low-density
lipoprotein (LDL) cholesterol and apolipoprotein (apo) B; high triglycerides, low high-density
lipoprotein (HDL) cholesterol and apoA1; and high lipoprotein(a) (lp[a]). We performed a
controlled multicentric trial in India to evaluate the efficacy and safety of a fixed dose
combination of lovastatin and niacin extended release (niacinER) formulation in patients with
moderate to severe dyslipidemia. Consecutive subjects that satisfied the selection criteria,
agreed to an informed consent, and with no baseline presence of liver/renal disease or heart
failure were enrolled in the study. After a 4-week run-in period there were 142 patients with
LDL levels ≥ 130 mg/dL. Eleven patients were excluded because of uncontrolled hyperglycemia
and 131 patients were recruited. After baseline evaluation of clinical and biochemical
parameters all subjects were administered lovastatin (20 mg) and niacinER (500 mg) combination
once daily. Dose escalation was done on basis of lipid parameters at 8 weeks and in 11 patients
increased to lovastatin (20 mg) and niacinER (1000 mg). An intention-to-treat analysis was
performed and data was analyzed using nonparametric Wilcoxon signed rank test. Thirteen
patients (10%) were lost to follow-up and 4 (3%) withdrew because of dermatological adverse
effects: flushing, pruritus, and rash. The mean values of various lipid parameters (mg/dL) at
baseline, and at weeks 4, 12, and 24 respectively were: total cholesterol 233.9 ± 27, 206.3 ± 27,
189.8 ± 31, and 174.9 ± 27 mg/dL; LDL cholesterol 153.4 ± 22, 127.3 ± 21, 109.2 ± 27, and
95.1 ± 23 mg/dL; triglycerides 171.1 ± 72, 159.5 ± 75, 149.2 ± 45, and 135.2 ± 40 mg/dL; HDL
cholesterol 45.6 ± 7, 48.9 ± 7, 51.6 ± 9, and 53.9 ± 10 mg/dL; lp(a) 48.5 ± 26, 40.1 ± 21, 35.4 ± 21,
and 26.9 ± 19 mg/dL; and apoA1/apoB ratio 0.96 ± 0.7, 1.04 ± 0.4, 1.17 ± 0.5, and 1.45 ± 0.5
(p < 0.01). The percentage of decline in various lipids at 4, 12, and 24 weeks was: total
cholesterol 11.8%, 18.8%, and 25.2%; LDL cholesterol 17.0%, 28.8%, and 38.0%; triglyceride
6.8%, 12.8%, and 21.0%; lp(a) 17.5%, 26.9%, and 44.5% respectively (p < 0.01). HDL
cholesterol and apoA1/apoB increased by 7.2%, 13.1%, and 18.2%; and 7.9%, 21.9%, and
51.6% respectively (p < 0.01). Target LDL levels (< 100 mg/dL in subjects with manifest
coronary heart disease or diabetes; < 130 mg/dL in subjects with > 2 risk factors) were achieved
in 92 (80.7%) patients. No significant changes were observed in systolic or diastolic blood
pressure, blood creatinine, transaminases, or creatine kinase. A fixed dose combination of
lovastatin and niacinER significantly improved cholesterol lipoprotein lipids as well as lp(a)
and apoA1/apoB levels in Asian Indian dyslipidemic patients. Satisfactory safety and
tolerability profile in this population was also demonstrated.
Keywords: Hypercholesterolemia, South Asians, coronary heart disease, lipid abnormalities,
low HDL, lipoprotein(a)
Introduction
Asian Indian dyslipidemia is characterized by moderate to high low-density lipoprotein
(LDL) cholesterol, raised small-dense LDL particles, low high-density lipoprotein
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(HDL) cholesterol, high triglyceride, and high lipoprotein(a)
(lp [a]) (Bhatnagar 1998). This constellation of abnormal-
ities is also known as atherogenic dyslipidemia and is part
of the metabolic syndrome (Grundy 2004). Case-control
studies within India have also reported that characteristic
lipid abnormalities in patients with coronary heart disease
are low HDL cholesterol and apolipoprotein (apo) A, and
high basal and post-prandial triglycerides, lp(a), and apoB
(Kumar et al 1976; Wasir et al 1987; Vashist et al 1990;
Sahi et al 1993; Pais et al 1996; Dhanjal et al 2001; Gupta
et al 2001), and abnormalities of apo E4 allele on genetic
evaluation (Luthra et al 2002; Kumar et al 2003).
For the last ten years, statins or hydroxymethyl glutyrate
co-enzyme A (HMG CoA) reductase inhibitors have been
the mainstay of lipid management in patients with
dyslipidemias and coronary heart disease (NCEP 2002;
Pasternak et al 2002; Jones 2004). However, statins when
used in large doses have significant side effects that include
rhabdomyolysis and liver function abnormalities (Pasternak
et al 2002; Botorrof 2004). The Third Adult Treatment Panel
(ATP-III) of the American National Cholesterol Education
Program (NCEP) has focused on LDL cholesterol as the
primary treatment objective (NCEP 2002). The recent
revision of ATP has, however, also highlighted other lipid
abnormalities that are part of the metabolic syndrome and
advocated combination therapy to achieve lipid targets
(Deedwania et al 2004; Grundy et al 2004). Targets of LDL
cholesterol have been set at < 70 mg/dL (Cannon et al 2004;
Grundy et al 2004). Similar stringent targets are on the anvil
for other lipid fractions (triglycerides < 100 mg/dL; non-
HDL cholesterol < 100 mg/dL; HDL cholesterol > 60 mg/dL;
and Lp(a) < 20 mg/dL) (Gupta 2000; Deedwania et al 2004;
Deedwania and Gupta 2005).
 Combination therapy is more
relevant in the Indian context where a plethora of lipoprotein
abnormalities exist (Bhatnagar 1998; Gupta 2000; Gupta et
al 2001). One such combination with potential to reduce
LDL cholesterol, non-HDL cholesterol, and lp(a), and
increase HDL cholesterol is lovastatin with niacin (NCEP
2002; Deedwania et al 2004; Jones 2004). Previous studies
have shown that usual doses of niacin are associated with
significant vascular and dermatological side effects and a
slow release formulation has been developed that is
associated with low incidence of side effects of this type
(Kashyap et al 2002; NCEP 2002). This combination has
been reported to be safe and effective in Caucasian
populations in many trials (Kashyap et al 2002; Jones 2004),
however, no such study is available from India. Therefore,
we performed a controlled multicentric trial to study the
efficacy and safety of a fixed dose lovastatin and niacin
extended release (niacinER) combination.
Methods
Study design
This was a 24-week open labeled, multicentric, non-
comparative; nonrandomized study approved by the Drug
Controller General of India and respective Institutional
Ethics Committees and was conducted in accordance with
the guideline of good clinical practice and the Helsinki
Declaration. All patients were recruited after obtaining
written informed consent before their participation. The
study included men and women > 21 years age willing to
complete a 4-week run-in period. Participants were required
to fulfill one of the following three criteria: (1) manifest
coronary heart disease or diabetes and LDL cholesterol
> 130 mg/dL; (2) ≥ 2 coronary risk factors and LDL
cholesterol > 160 mg/dL in subjects with no preexisting
coronary disease or diabetes; or (3) < 2 coronary risk factors,
LDL cholesterol > 190 mg/dL and no evidence of coronary
disease or diabetes. Exclusion criteria included pregnant
women, serum triglycerides > 800 mg/dL, HDL cholesterol
> 70 mg/dL, evident liver dysfunction or elevation in hepatic
enzymes, recent myocardial infarction, stroke or bypass graft
within 6 months, recent acute arterial hemorrhage,
uncontrolled grade III hypertension, uncontrolled cardiac
arrhythmia, uncontrolled diabetes, active gall bladder
disease, peptic ulcer disease, history of recent gout attack,
hypothyroidism not managed with stable thyroxin doses,
concomitant use of other investigational agent or
dyslipidemic medication, or concurrent therapy with agents
having potential to cause drug-drug interactions
(isotretinoin, cyclosporine, troglitazone, macrolide
antibiotics, and azole-antifungal medications). Patients were
informed that they were free to withdraw from the study at
any time without stating the reason. The investigator could
withdraw a subject from the study if he suffered from
significant illness during the course of the study, experienced
serious adverse effects, or withdrawal was in best interest
of the patient. In case the patient did not come for follow
up, he was treated as a drop out from the study. 142 patients
were screened for the study and included for the initial run-
in phase.
Assessments
Symptoms and demographic data were recorded at
enrolment. Physical examination, 12-lead electrocardiography,Vascular Health and Risk Management 2006:2(1) 89
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urinalysis, hematological examinations (blood counts,
sedimentation rate), and chest radiography were performed
at the beginning and at 24 weeks (end of trial). Plasma lipids,
total cholesterol, triglycerides, HDL cholesterol, LDL
cholesterol, apoA1, apoB, and lp(a) were measured at
baseline and after weeks 4, 12, and 24 of drug therapy. All
the biochemical investigations were standardized across sites
by using internal and external quality control measures.
ApoA1, apoB, and lp(a) were estimated by nephelometry
and immunoturbidimetry using Randox
® kit. The intraassay
and interassay coefficient of variations respectively were:
apoA1 2.13%–2.78% and 2.65%–2.98%; apoB 1.82%–4.50%
and 5.65%–6.69%; lp(a) 6.55%–10.34% and 13.61%–16.26%.
Evaluation of hepatic functions (transaminases, alkaline
phosphatase, prothrombin time), renal functions (creatinine,
urea, uric acid), and creatine kinase, and vital signs (pulse
and blood pressure) was also performed at baseline and
weeks 4, 12, and 24. Patients were also advised to visit at
the 16th week when additional adverse drug reaction
monitoring was performed. Primary and secondary end
points of the trial were evaluation of efficacy and safety of
the drug combination. Efficacy was assessed by the
achievement of goals according to the NCEP (2002)
guidelines. Safety was evaluated as nonoccurrence of any
drug related adverse effects using clinical and laboratory
investigations.
Intervention
A fixed dose combination (FDC) of lovastatin (20 mg) and
niacinER (500 mg) was administered once daily with a low
fat snack at bedtime. The physicochemical characteristics
of this extended release form of niacin were comparable
with the internationally available niacin formulation:
Niaspan
® (Panacea-Biotec 2004). Dose escalation was done
on the basis of LDL cholesterol levels at week 8 of therapy.
In coronary disease or diabetic subjects who did not achieve
LDL cholesterol of < 100 mg/dL, or non-diabetic or non-
coronary disease subjects with ≥ 2 risk factors and LDL
cholesterol < 130 mg/dL, the dose of niacin was increased.
During first dose escalation FDC of lovastatin (20 mg) and
niacin
ER (l000 mg) was used and dose greater than
40/2000 mg was not recommended. Use of aspirin was
permitted 30 minutes before dosing to prevent flushing.
Statistical analysis
A sample size of 120 subjects was considered adequate for
the study statistical power. Descriptive statistics (number,
mean, standard deviation) have been presented. Pre- and
post-intervention comparison was done using nonparametric
Wilcoxon signed rank test. P < 0.05 was considered
significant.
Results
Of the 142 subjects eligible for enrollment in the study, 11
were not initiated into the study due to poor glycemic
control. The mean age of subjects was 52.6 ± 11.1 years,
weight 67.6 ± 10.1 kg, and height 1.64 ± 0.1 m. Fifty-three
(40.4%) subjects had body mass index ≥ 25 kg/m
2,
concomitant hypertension was in 53 (40.4%), diabetes in
28 (21.4%), coronary artery disease in 60 (45.8%),
controlled hypothyroidism in 1 (0.8%), and 72 (55.0%) were
on aspirin. Of these 131 patients, 4 withdrew from the study
because of dermatological adverse effects, and 13 were lost
to follow up. The baseline characteristics of the 13 patients
who were lost to follow up did not differ significantly from
those who continued in the study. The mean age of this
group was 50.8 ± 9 years, weight 69.4 ± 13.6 kg, total
cholesterol 227.6 ± 22 mg/dL, triglycerides 196.8 ± 84 mg/dL,
HDL cholesterol 43.1 ± 10.1 mg/dL, LDL cholesterol
149.3 ± 14.8 mg/dL, lp(a) 51.3 ± 20.1 mg/dL and apoA1/apoB
was 0.82 ± 0.39 (see Table 1 for comparison). Thus, at the
end of the study a total of 114 subjects were available for
efficacy and safety evaluations.
The mean values of various lipid parameters at baseline,
and weeks 4, 12, and 24 are shown in Table 1. The values of
various lipoprotein lipids respectively were: total cholesterol
233.9 ± 27, 206.3 ± 27, 189.8 ± 31, and 174.9 ± 27 mg/dL;
LDL cholesterol 153.4 ± 22, 127.3 ± 21, 109.2 ± 27, and
95.1 ± 23 mg/dL; triglycerides 171.1 ± 72, 159.5 ± 75,
149.2 ± 45, and 135.2 ± 40 mg/dL; HDL cholesterol 45.6 ± 7,
48.9 ± 7, 51.6 ± 9, and 53.9 ± 10 mg/dL; lp(a) 48.5 ± 26,
40.1 ± 21, 35.4 ± 21, and 26.9 ± 19 mg/dL; and the ratio of
apoA1/apoB were 0.96 ± 0.7, 1.04 ± 0.4, 1.17 ± 0.5, and
1.45 ± 0.5 (p < 0.01). The percentage of decline in various
lipids at 4, 12, and 24 weeks were for total cholesterol
11.8%, 18.8%, and 25.2%; LDL cholesterol 17.0%, 28.8%,
and 38.0%; triglyceride 6.8%,12.8%, and 21.0%; lp(a)
17.5%, 26.9%, and 44.5% respectively (p < 0.01). HDL
cholesterol and apoA1/apoB increased by 7.2%, 13.1%, and
18.2%; and 7.9, 21.9 and 51.6% respectively (p < 0.01)
(Figure 1). Of the 114 patients who were available at end of
the trial, 92 patients (80.7%) achieved the target LDL
cholesterol goals according to the NCEP ATP-III guidelines
(NCEP 2002).Vascular Health and Risk Management 2006:2(1) 90
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Overall, treatment with lovastatin and niacin
ER FDC was
well tolerated with no persistent or unexpected adverse drug
reactions. Twenty-six patients (19.8%) reported minor
adverse events; most were gastrointestinal (nausea,
vomiting, dyspepsia) and dermatologic (pruritus, rash,
flushing). Other adverse events were myalgia (2 subjects).
Flushing caused 3 patients to withdraw from the study. One
patient withdrew because of pruritus and rash; this patient
was receiving the combination containing 1000 mg niacin.
Clinical myopathy was not observed in any of the subjects.
Haematological and biochemical changes are reported in
Table 2.
Discussion
This study shows that a combination of lovastatin and low-
dose niacin is effective in ameliorating the Asian Indian type
of dyslipidemia. The pattern of dyslipidemia seen in Asian
Indians is different from observed in other ethnic groups
and is also the dyslipidemia of metabolic syndrome (Grundy
2004). Lovastatin and niacin in low doses used in the present
study resulted in a significant decline in LDL cholesterol,
triglycerides, and lp(a) along with an increase in HDL
cholesterol and apoA1/apoB ratio.
Combination therapy for the treatment of dyslipidemias
associated with coronary artery disease, diabetes, and
hypertension is a widely used strategy to promote effective
treatment in patients with disturbances in more than one
lipid parameter (Deedwania et al 2004). Combination
therapy allows the physician to take advantage of the
independent effects of the therapies selected. An additive
and possibly synergistic LDL cholesterol lowering effect
may be achieved by using drugs that individually lower LDL
cholesterol, but by different mechanisms. Additionally,
different lipid parameters such as HDL cholesterol and
triglycerides may also be corrected by using combination
therapies. The combination of lovastatin and niacinER is the
first hypolipidemic combination approved by the American
Federal Drug Administration. Various studies have
demonstrated that the efficacy of this combination is better
than either of the two agents used alone (Guyton et al 1998;
Chong and Bachenheimer 2000; Gupta and Ito 2002;
Kashyap 2002; NCEP 2002).
Niacin inhibits hepatic triglyceride synthesis and results
in reduced production of apoB-containing lipoproteins.
Niacin is considered an excellent choice in increasing HDL
cholesterol and is effective in reducing lp(a); an important
emerging risk factor. Lovastatin is known to upregulate LDL
receptors, which results in increased LDL and apoB
catabolism. Therefore, this lipid modifying drug
combination is ideal for improvement of the multiple
coexistent lipid abnormalities frequently encountered in
Indian population (Deedwania and Gupta 2005). The
combined administration of a statin and nicotinic acid was
first described over 15 years ago (Henkin et al 1991). A
year-long open label study showed that concomitant
administration of lovastatin, pravastatin, or simvastatin with
niacin decreased LDL cholesterol to a greater extent than
Table 1 Various lipoprotein lipids (mean ± 1 standard deviation) at baseline and after 4-week, 12-week, and 24-week treatment
with lovastatin and niacin combination
Parameter Baseline Week 4 Week 12 Week 24
(mg/dL) (n = 131) (n = 120) (n = 115) (n = 114)
Total cholesterol 233.9 ± 27.4 206.3 ± 27.4* 189.8 ± 31.3* 174.9 ± 27.2*
Triglycerides 171.1 ± 72.2 159.5 ± 75.0* 149.2 ± 45.0* 135.2 ± 40.5*
HDL cholesterol 45.6 ± 7.4 48.9 ± 7.4* 51.6 ± 8.7 * 53.9 ± 9.5*
LDL cholesterol 153.4 ± 21.9 127.3 ± 20.8* 109.2 ± 26.8* 95.1 ± 23.1*
ApoA1/B 0.96 ± 0.67 1.04 ± 0.42* 1.17 ± 0.49* 1.45 ± 0.51*
Lipoprotein (a)  48.5 ± 26.4 40.1 ± 21.2* 35.4 ± 20.6* 26.9 ± 19.2*
*p  < 0.05.
Abbreviations: HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; Apo, apolipoprotein.
-11
-18
-25
-18
-30
-38
5
12
18
-10
-15
-21
-18
-28
-44
8
21
52
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
Cholesterol LDL cholesterol HDL cholesterol Triglycerides Lp(a) ApoA1/B
4 weeks 12 weeks 24 weeks
P
e
r
c
e
n
t
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
v
a
l
u
e
s
Figure 1 Percent change in various lipid levels. There is significant change in
all the lipid parameters when compared with baseline at weeks 4, 12, and 24
(p < 0.01).Vascular Health and Risk Management 2006:2(1) 91
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niacin
ER alone in hypercholesterolemic patients (–32% vs
–18%) without unduly increasing the frequency of adverse
events (Guyton et al 1998). Drug withdrawal was observed
in 5% subjects. This is similar to the present study where
LDL cholesterol decreased by 38% over a 6-month period
and drug withdrawal was observed in 3% of cases. Ten
percent dropped out of the study due to unspecified reasons
and it is not clear whether this was due to adverse events or
other issues of compliance.
There are studies that have compared the effects of statin-
niacin combination therapy with statin alone. Three were
placebo controlled randomized trials (Davignon et al 1994;
O’Keefe et al 1995; Vacek et al 1995), one was an open
label study (Illingworth and Bacon 1989) and one was a
retrospective analysis (Wolfe et al 2001). In these five
studies, the combination of nicotinic acid with a statin
resulted in greater decreases in LDL cholesterol and
triglycerides, and greater increase in HDL cholesterol than
occurred with statin monotherapy. Decreases in LDL
cholesterol and increases in HDL cholesterol tended to be
marked with high doses of niacin. At higher doses of niacin,
the frequency of adverse events and drop-out rate was greater
in those with combination therapy than those on statin alone,
although statin use was associated with greater incidence
of abnormal transaminases. As we did not use a control
group with statins only, we cannot comment on this
observation. Published studies also report that LDL lowering
effects of statin-niacin combination were only slightly
greater (10%) than achieved with statins alone and the
combination was not recommended for LDL cholesterol
lowering (Thompson 2004). In patients with raised
triglycerides and low HDL cholesterol, which is the typical
dyslipidemia of Asian Indians, and the metabolic syndrome,
there are major benefits of this combination as decreases in
triglycerides and increases in HDL approach 25%, which
more than compensates for the side effects of niacin. The
present study also demonstrates that this fixed drug
combination causes a significant decline in lp(a) (–44%)
and increase in the apoA1/apoB ratio (–52%), which are
major benefits not reported previously. This study also shows
that there is increasing efficacy of this drug combination
and a trend towards a continued decline in LDL cholesterol,
triglycerides, and lp(a), and an increase in HDL cholesterol
and apoA1. Similar trends have been previously reported
in short term studies (Chong and Bachenheimer 2000). In
long term studies, it has been reported that the initial large
decline tends to attenuate with time (Warnica 2004).
In the present study this combination in a lower dose
was used to generate data in the Asian Indian population.
At the end of weeks 4, 12, and 24, statistically significant
changes were observed in the levels of LDL cholesterol,
HDL cholesterol, triglycerides, apoA1/apoB ratio, and lp(a).
The maximum change was observed towards end of the
study. The target LDL cholesterol levels, as recommended
by NCEP (2002) were achieved in more than 80% of the
patients evaluated in the study. Dose escalation was needed
on basis of serum lipid parameters in 11 patients only. In
our study, the number of female patients was low and they
were not analyzed separately. There are several limitations
in the study. We used an open-labeled design with no blinded
placebo group. This can lead to biased physician recruitment,
such as the noninclusion of patients with severe hyper-
cholesterolemia leading to more patients achieving the lipid
targets, as well as greater reporting of niacin-related side
effects. However, the present study design was important,
as this was a regulatory post-marketing trial. All the
laboratory investigations were blinded. Also the focus of
the study was the amelioration of typical Asian Indian
Table 2 Effect of lovastatin – niacin combination tablet on selected laboratory parameters
Baseline* Week 24*
(n = 131) Week 4 Week 8 Week 12 (n = 114) Normal range
Hemoglobin (gm/dl) 11.7 ± 1.6 – – – 11.8 ± 1.4 14 g%–18 g%
White cell count (cells/cmm) 7461 ± 1426 – – – 6998 ± 1323 4300–10800/mm3
ESR (mm 1st hour) 24.5 ± 12.3 – – – 17.2 ± 10.2 0–20 mm in 1st hr
SGOT (IU/l) 29.9 ± 10.0 29.3 ± 9.3 29.5 ± 12.5 30.1 ± 14.4 24.5 ± 7.4 0–35 IU/L
SGPT (lU/l) 31.5 ± 12.7 29.2 ± 9.5 28.1 ± 8.8 28.0 ± 9.5 23.0 ± 8.0 0–35 IU/L
Alkaline Phosphatase (lU/l) 113.3 ± 51.9 107.1 ± 43.7 101.2 ± 38.7 94.5 ± 30.2 91.1 ± 34.6 60–306 lU/L
Creatinine (mg/dL) 0.93 ± 0.2 0.96 ± 0.7 1.01 ± 6.5 1.06 ± 0.7 1.01 ± 0.6 < 1.5 mg/dL
Uric acid (mg/dL) 4.5 ± 1.1 4.4 ± 0.9 4.5 ± 0.9 4.4 ± 0.8 4.4 ± 1.0 2.5–8.0 mg/dL
Creatine kinase (mg/dL) 146.3 ± 70.5 134.7 ± 62.5 130.0 ± 55.5 125.6 ± 50.7 115.3 ± 40.5 24–190 IU/L
Glucose fasting (mg/dL)  90.3 ± 14.7 – – – 81.1 ± 23.5 <110 mg/dL
*Mean ± 1 standard deviation
Abbreviations: ESR, erythrocyte sedimentation rate; SGOT, serum aspartate aminotransferase; SGPT, serum alanine aminotransferase.Vascular Health and Risk Management 2006:2(1) 92
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dyslipidemia, which is characterized by low HDL
cholesterol, high triglycerides, and lp(a). Statins have been
reported to be of insignificant benefit in these lipid
abnormalities; therefore no control group with statins was
included. It is also possible that dietary changes and more
exercise were performed in the study patients leading to
large benefits as seen in the present study. The diet – exercise
advice was given uniformly to all the patients. In a subgroup
of patients where dietary patterns and exercise were
evaluated (Bhargava 2004) in detail it was noted that the
change in diet was the greatest in the first two weeks,
followed by a gradual reversal to baseline levels with time,
hence, the influence of lifestyle changes appears minimal.
The number of subjects in the present study is also small
and larger studies are needed to more definitively answer
the study question.
Overall, this study demonstrates that the low dose
combination offers an effective control of LDL cholesterol
besides providing additional benefits in terms of reduced
triglycerides, lp(a), and increased HDL cholesterol and
apoA1/apoB ratio. Latter findings have special relevance in
context of Asian Indian dyslipidemia as well as insulin
resistance syndrome and the metabolic syndrome.
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